Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases

Goenka, Vidul; Borkar, Tanhai; Desai, Aska; Das, Raunak Kumar

doi:10.1007/s40200-020-00647-5

Cited by 4 publications

(5 citation statements)

References 191 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, such delivery systems do not eliminate hyperglycemic complications such as nephropathy and ketoacidosis. Additionally, the dosage and onset of action of administered insulin are completely different from the physiological level of insulin action [6,7]. Treating T1DM by pancreatic transplantation is also limited due to the lack and shortage of tissue donors in addition to the risk of immunological rejection [6,8,9].…”

Section: Introductionmentioning

confidence: 99%

“…Additionally, the dosage and onset of action of administered insulin are completely different from the physiological level of insulin action [6,7]. Treating T1DM by pancreatic transplantation is also limited due to the lack and shortage of tissue donors in addition to the risk of immunological rejection [6,8,9]. As a result, studies are being conducted to see if the differentiation potential of mesenchymal stem cells (MSCs) may be used to treat T1DM [10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, the latest studies have revealed that MSCs implantation could be used as a recent therapeutic intervention for DM by lowering blood glucose levels through paracrine impacts rather than direct transdifferentiation into insulin-producing cells (IPCs) [17][18][19][20]. Nowadays, using IPCs is considered a new approach to an effective therapy for both kinds of DM which is mainly derived from the multipotent character of MSCs [6]. Cell-based therapies also demonstrated a potential approach to T2DM treatment through generating an infinite supply of insulin-producing cells, mending β cell function, modifying metabolism, and alleviating immunological dysfunction [21,22].…”

Section: Introductionmentioning

confidence: 99%

“…Cell-based therapies also demonstrated a potential approach to T2DM treatment through generating an infinite supply of insulin-producing cells, mending β cell function, modifying metabolism, and alleviating immunological dysfunction [21,22]. MSCs have been considered a favorite type of stem cell among researchers because of their hypo-immunogenic properties, multipotent character, and relative abundance in human tissue [6]. MSCs can develop into IPCs in T2DM.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The effect of diabetes mellitus on differentiation of mesenchymal stem cells into insulin-producing cells

Badr,

Kamal,

El-Maraghy

et al. 2024

Biol Res

View full text Add to dashboard Cite

Background Diabetes mellitus (DM) is a global epidemic with increasing incidences. DM is a metabolic disease associated with chronic hyperglycemia. Aside from conventional treatments, there is no clinically approved cure for DM up till now. Differentiating mesenchymal stem cells (MSCs) into insulin-producing cells (IPCs) is a promising approach for curing DM. Our study was conducted to investigate the effect of DM on MSCs differentiation into IPCs in vivo and in vitro. Methods We isolated adipose-derived mesenchymal stem cells (Ad-MSCs) from the epididymal fat of normal and STZ-induced diabetic Sprague–Dawley male rats. Afterwards, the in vitro differentiation of normal-Ad-MSCs (N-Ad-MSCs) and diabetic-Ad-MSCs (DM-Ad-MSCs) into IPCs was compared morphologically then through determining the gene expression of β-cell markers including neurogenin-3 (Ngn-3), homeobox protein (Nkx6.1), musculoaponeurotic fibrosarcoma oncogene homolog A (MafA), and insulin-1 (Ins-1) and eventually, through performing glucose-stimulated insulin secretion test (GSIS). Finally, the therapeutic potential of N-Ad-MSCs and DM-Ad-MSCs transplantation was compared in vivo in STZ-induced diabetic animals. Results Our results showed no significant difference in the characteristics of N-Ad-MSCs and DM-Ad-MSCs. However, we demonstrated a significant difference in their abilities to differentiate into IPCs in vitro morphologically in addition to β-cell markers expression, and functional assessment via GSIS test. Furthermore, the abilities of both Ad-MSCs to control hyperglycemia in diabetic rats in vivo was assessed through measuring fasting blood glucose (FBGs), body weight (BW), histopathological examination of both pancreas and liver and immunoexpression of insulin in pancreata of study groups. Conclusion Our findings reveal the effectiveness of N-Ad-MSCs in differentiating into IPCs in vitro and controlling the hyperglycemia of STZ-induced diabetic rats in vivo compared to DM-Ad-MSCs. Graphical Abstract

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The effect of diabetes mellitus on differentiation of mesenchymal stem cells into insulin-producing cells

Badr,

Kamal,

El-Maraghy

et al. 2024

Biol Res

View full text Add to dashboard Cite

show abstract

“…Mesenchymal stem cells (MSCs) possess excellent therapeutic potential. Their immunomodulatory and regenerative potential is well documented across multiple tissues (Kangari et al, 2020), organ systems (Abdi et al, 2008;Yan et al, 2013;Goenka et al, 2020) and diseases (Guo et al, 2020;Hmadcha et al, 2020;Lim and Khoo, 2021;Paris et al, 2021). As a result, MSCs have been explored extensively in clinical trials (Jin and Lee, 2018).…”

Section: Introductionmentioning

confidence: 99%

Micro RNA based MSC EV engineering: Targeting the BMP2 cascade for bone repair

Huang

Kang²,

Leung³

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Mesenchymal stem cell derived extracellular vesicles (MSC EVs) possess excellent immunomodulatory and therapeutic properties. While beneficial, from a translational perspective, extracellular vesicles with consistent functionality and target specificity are required to achieve the goals of precision medicine and tissue engineering. Prior research has identified that the miRNA composition of mesenchymal stem cell derived extracellular vesicles contributes significantly towards extracellular vesicles functionality. In this study, we hypothesized that mesenchymal stem cell derived extracellular vesicle functionality can be rendered pathway-specific using a miRNA-based extracellular vesicles engineering approach. To test this hypothesis, we utilized bone repair as a model system and the BMP2 signaling cascade as the targeted pathway. We engineered mesenchymal stem cell extracellular vesicles to possess increased levels of miR-424, a potentiator of the BMP2 signaling cascade. We evaluated the physical and functional characteristics of these extracellular vesicles and their enhanced ability to trigger the osteogenic differentiation of naïve mesenchymal stem cell in vitro and facilitate bone repair in vivo. Results indicated that the engineered extracellular vesicles retained their extracellular vesicles characteristics and endocytic functionality and demonstrated enhanced osteoinductive function by activating SMAD1/5/8 phosphorylation and mesenchymal stem cell differentiation in vitro and enhanced bone repair in vivo. Furthermore, the inherent immunomodulatory properties of the mesenchymal stem cell derived extracellular vesicles remained unaltered. These results serve as a proof-of-concept for miRNA-based extracellular vesicles engineering approaches for regenerative medicine applications.

show abstract

Free Fatty Acids from Type 2 Diabetes Mellitus Serum Remodel Mesenchymal Stem Cell Lipids, Hindering Differentiation into Primordial Germ Cells

Norouzi

Zarezadeh

Mehdizadeh

et al. 2022

Appl Biochem Biotechnol

View full text Add to dashboard Cite

Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases

Cited by 4 publications

References 191 publications

The effect of diabetes mellitus on differentiation of mesenchymal stem cells into insulin-producing cells

The effect of diabetes mellitus on differentiation of mesenchymal stem cells into insulin-producing cells

Micro RNA based MSC EV engineering: Targeting the BMP2 cascade for bone repair

Free Fatty Acids from Type 2 Diabetes Mellitus Serum Remodel Mesenchymal Stem Cell Lipids, Hindering Differentiation into Primordial Germ Cells

Contact Info

Product

Resources

About